Website available soon.
Thanks for the visit!


FASTinov is a R&D intensive Startup with a patented disruptive technology to perform fast and reliable antimicrobial susceptibility tests in acute care settings.

Context : The global emergence and spread of antimicrobial resistance is a major medical and economic problem . When an infection is diagnosed, the physician is required to start an empiric larg e spectrum therapy, since current comprehensive and proven susceptibility profile methods require, at least, 48h.

FASTinov approach : In order to support clinical decisions with a fast turnaround time, FASTinov offers a unique time-saving and comprehensive solution starting directly from positive blood cultures. FASTinov innovative approach allows for the determination of the susceptibility phenotype in 2 hours, compared with +48 hours needed for current standard methods.


Disruptive Technology : “FAST ” patented methodology (Flow Cytometry Antimicrobial Susceptibility Test) fills a gap in existing AST methods: microbial cells can now be discriminated in terms of S usceptible vs R esistant phenotypes, independent of growth. FAST methodology provides the susceptibility profile in clinically useful time and clarifies the main resistance mechanism involved.


All-in-one kit : Sample prep, probes, antibiotics, reagents and a dedicated analytical software package developed by FASTinov allowing the test to become more automatized and operator independent and provides clear guidance for the best use of antibiotics based on established international recommendations from EUCAST and CLSI.


Value Proposition : By providing a fast susceptibility profile and guidance support for clinical prescriptions and decisions in acute care settings, FASTinov strongly contributes to the reduction of: i ) medication costs; ii) clinical therapeutical failure; iii) diagnostic and hospitalization costs; iv) antimicrobial resistance; v) spread of multi-resistant strains.


FASTinov patented methodology is based on an early detection of microbial cell lesions or metabolic changes, relying on fluorochromes that target specific changes and make this identifiable through flow cytometer analysis.​

IP Patent​
WO 2012164547 A1​


List of publications of the group regarding:


  • Gram negative bacteria and Flow cytometry
  1. Rapid flow cytometry test for identification of different carbapenemases in Enterobacteriaceae. 2016, Antimicrob Agents Chemother. 2016 Mar 28. pii: AAC.02947-15. [Epub ahead of print]

  2. Clinical and economical impact of a rapid susceptibility testing regarding blood cultures with Gram negative bacilli. 26th ECCMID, Amsterdam, Netherlands, 2016.

  3. Rapid antimicrobial susceptibility profile directly from positive blood cultures using flow cytometry. 25th ECCMID, Copenhagen, Denmark, 2015.

  4. Rapid detection of extended-spectrum b-lactamase producing bacteria by means of flow cytometry. Clin Microbiol Infect. 2013 Jan;19(1):E8-E15.


  • Gram positive bacteria and Flow cytometry
  1. A rapid flow cytometry test for detection of vancomycin and linezolid-resistance among Gram-positive bacteria. 23th ECCMID, Berlin, Germany, 2013.

  2. Rapid antimicrobial susceptibility profile directly from positive blood cultures using flow cytometry. 25th ECCMID, Copenhagen, Denmark, 2015.


  • Yeasts and Flow cytometry
  1. Evaluation of antifungal susceptibility using flow cytometry. Methods Mol Biol. 2010, 638:281-9.

  2. Comparison of two probes for testing susceptibilities of pathogenic yeasts to voriconazole, itraconazole, and
    caspofungin by flow cytometry. J Clin Microbiol. 2005, 43(9):4674-9.

  3. Susceptibility to fluconazole of Candida clinical isolates determined by FUN-1 staining with flow cytometry and epifluorescence microscopy. J Med Microbiol. 2001, 50(4):375-82.

  4. Cytometric approach for a rapid evaluation of susceptibility of Candida strains to antifungals. Clin Microbiol Infect. 2001, 7(11):609-18.

  5. Specific detection of P. jiroveci on clinical samples by flow cytometry. Fungal Diagnostics: Methods and Protocols. 2013, 968:203-211.

Quality Policy

The Quality Policy of FASTinov is to improve health care by providing high quality, safe and effective diagnostic products.

This is achieved

  1. Through the processes of design, development, and manufacture carried out by competent and empowered staff.

  2. by striving for continuing quality improvement.

  3. by recognising that the involvement and commitment of all FASTinov personnel is essential.

  4. by providing appropriate training and an organizational structure which promotes empowerment.

  5. by assessment of and effective communication with suppliers and other stakeholders.

  6. by ensuring appropriate investment in technology and systems.

The team and management are highly committed to follow these policies. The Quality Policy is communicated to all employees and is reviewed at management Review Meetings.

Edifício UPTEC
Rua Alfredo Allen n 455/461, sala 17
4200-135 Porto

R. Dr. Francisco Sá Carneiro, 312 Loja C
4450-676 Leça da Palmeira, Matosinhos – Portugal

Skype: info.fastinov

Cidália Pina Vaz
CEO & Co-founder
mobile: (+351) 924 393 147
Antonio Soares
Executive Board Member
mobile: (+351) 966 321 139
© 2016 FASTinov